natgillin/translations-raw huggingface dataset:
In addition to being a potent inhibitor of bone resorption, zoledronic acid also possesses several antitumour properties that could contribute to its overall efficacy in the treatment of metastatic bone disease. 
Osim što je potentni inhibitor resorpcije kosti, zoledronatna kiselina također ima nekoliko antitumorskih svojstava koja bi mogla pridonositi njezinoj sveukupnoj djelotvornosti u liječenju metastatske koštane bolesti.
Statistically significant differences are marked (*p<0.05) for between treatment comparisons (4 mg zoledronic acid vs. placebo) 
Označene su statistički značajne razlike (*p < 0,05) između dvije terapije usporedbe (4 mg zoledronatne kiseline naspram placeba)
− Low level of calcium in the blood. 
- niska razina kalcija u krvi.
Acute phase reaction, pain 
reakcija akutne faze, bol
At the request of the European Medicines Agency, Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached. 
• prilikom svake izmjene sustava za upravljanje rizikom, a naročito kada je ta izmjena rezultat primitka novih informacija koje mogu voditi ka značajnim izmjenama omjera korist/rizik, odnosno kada je izmjena rezultat ostvarenja nekog važnog cilja (u smislu farmakovigilancije ili minimizacije rizika).
Zoledronic Acid Hospira can be given to people aged 65 years and over. 
Zoledronatna kiselina Hospira može se davati osobama u dobi od 65 ili više godina.
- After opening the bag, the product should be used immediately in order to avoid microbial contamination. 
- Nakon otvaranja vrećice, lijek treba odmah primijeniti kako bi se izbjeglo mikrobiološko onečišćenje.
There was no accumulation of zoledronic acid in plasma after multiple doses given every 28 days. 
Nije došlo do akumulacije zoledronatne kiseline u plazmi nakon višestrukih doza koje se primjenjuju svakih 28 dana.
If hypocalcaemia, hypophosphataemia, or hypomagnesaemia occurs, short-term supplemental therapy may be necessary. 
Ako se razviju hipokalcemija, hipofosfatemija ili hipomagnezijemija, možda bude potrebna kratkotrajna terapija njihovim nadomjescima.
Any unused solution should be discarded. 
Svu neiskorištenu otopinu treba baciti.
1 intravenous bag 
1 intravenska vrećica
Bone biopsy results showed bone of normal quality with no evidence of impaired bone remodelling and no evidence of mineralisation defects. 
Rezultati biopsije kosti pokazali su kost normalne kvalitete bez dokaza oštećenog remodeliranja kosti kao i bez dokaza defekata mineralizacije.
The inter- and intra-subject variation for plasma clearance of zoledronic acid was shown to be 36% and 34%, respectively. 
Pokazalo se da inter- i intra-individualno variranje u klirensu zoledronatne kiseline iz plazme je 36%, odnosno 34%.
In a large clinical trial in 7,736 patients, osteonecrosis of the jaw has been reported in one patient treated with zoledronic acid and one patient treated with placebo. 
U velikom kliničkom ispitivanju na 7736 bolesnika, osteonekroza čeljusti je prijavljena u jednog bolesnika liječenih zoledronatnom kiselinom i jednog bolesnika koji je primao placebo.
Bone histology was evaluated in 7 patients with Paget's disease 6 months after treatment with 5 mg zoledronic acid. 
Histologija kosti procijenjena je u 7 bolesnika s Pagetovom bolešću 6 mjeseci nakon liječenja s 5 mg zoledronatne kiseline.
Incidence of individual adverse reactions following the first infusion was: fever (17.1%), myalgia (7.8%), flu-like symptoms (6.7%), arthralgia (4.8%) and headache (5.1%). 
Incidencija pojedinih nuspojava nakon prve infuzije bila je: vrućica (17,1%), mialgija (7,8%), simptomi nalik gripi (6,7%), artralgija (4,8%) i glavobolja (5,1%).
Angioneurotic oedema 
angioneurotski edem
oC after dilution 
oC nakon razrjeđivanja.
For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. 
U bolesnika koji razviju osteonekrozu čeljusti za vrijeme terapije bisfosfonatima, stomatološki kirurški zahvat može pogoršati stanje.
Clinical efficacy in the treatment of Paget's disease of the bone 
Klinička djelotvornost u liječenju Pagetove bolest kosti
- Carefully follow all the other instructions given to you by your doctor, nurse or pharmacist. 
- Pažljivo slijedite sve druge upute koje su Vam dali liječnik, medicinska sestra ili ljekarnik.
Each pack contains one vial with concentrate. 
Svako pakiranje sadrži jednu bočicu s koncentratom.
The long duration of action of zoledronic acid is attributable to its high binding affinity for the active site of farnesyl pyrophosphate (FPP) synthase and its strong binding affinity to bone mineral. 
Dugo trajanje djelovanja zoledronatne kiseline pripisuje se njenom visokom afinitetu vezanja na aktivno mjesto farnezil pirofosfat (FPP) sintaze i njenom snažnom afinitetu vezanja na mineral kosti.
The mechanism behind the increased incidence of atrial fibrillation in this single clinical trial is unknown. 
Mehanizam koji je dovodio do povećane incidencije fibrilacije atrija u tom jednom kliničkom ispitivanju je nepoznat.
− Talk to your doctor if you have ear pain, discharge from the ear, and/or an ear infection. 
Obratite se liječniku ako imate bol u uhu, iscjedak iz uha i/ili infekciju uha.
Hyperkalaemia, hypernatraemia 
hiperkalemija, hipernatremija
Solution for infusion 1 intravenous bag 
otopina za infuziju 1 intravenska vrećica
While the risk is reduced with a dose of zoledronic acid administered over 15 minutes, deterioration in renal function may still occur. 
Premda je rizik smanjen kod primjene zoledronatne kiseline primijenjene tijekom 15 minuta i dalje može nastupiti pogoršanje funkcije bubrega.
No teratological or embryo/foetal effects were observed in rabbits, although maternal toxicity was marked at 0.1 mg/kg due to decreased serum calcium levels. 
U kunića nisu opaženi teratološki ili embrio/fetalni učinci, iako je toksičnost za majku bila izrazita pri dozi od 0,1 mg/kg zbog smanjenih razina kalcija u serumu.
You may eat normally on the day you are treated with Zoledronic Acid Hospira. 
Možete normalno jesti na dan liječenja Zoledronatnom kiselinom Hospira.
While being treated with Zoledronic Acid Hospira, you should maintain good oral hygiene (including regular teeth brushing) and receive routine dental check-ups. 
Za vrijeme liječenja Zoledronatnom kiselinom Hospira, morate održavati dobru oralnu higijenu (uključujući redovito pranje zuba) i obavljati rutinske preglede kod zubara.
Follow all instructions given to you by your doctor, pharmacist or nurse carefully before you are given Zoledronic Acid Hospira. 
Pažljivo slijedite sve upute koje ste dobili od liječnika, ljekarnika ili medicinske sestre prije nego primijenite Zoledronatnu kiselinu Hospira.
The type of adverse reactions observed in this population were similar to those previously seen in adults with advanced malignancies involving the bone (see section 4.8). 
Vrsta nuspojava opažena u ove populacije bila je slična onima koje su prethodno viđene u odraslih bolesnika s uznapredovalom zloćudnom bolešću koja je zahvatila kost (vidjeti dio 4.8).
Your doctor may advise you to take calcium and vitamin D supplements (e.g. tablets) for at least the first ten days after being given Zoledronic Acid Hospira. 
Liječnik Vam može savjetovati da uzimate kalcij i vitamin D u obliku nadomjestaka prehrani (na primjer tableta) najmanje tijekom prvih deset dana nakon primjene Zoledronatne kiseline Hospira.
The study treatment period was 12 months preceded by a 4- to 9-week screening period during which vitamin D and elemental calcium supplements were taken for at least 2 weeks. 
Ispitivano liječenje trajalo je 12 mjeseci, a prethodilo mu je probirno razdoblje od 4 do 9 tjedana tijekom kojeg su bolesnici uzimali vitamin D i nadomjestke elementarnog kalcija tijekom najmanje 2 tjedna.
Re-treatment consists of an additional intravenous infusion of 5 mg zoledronic acid after an interval of one year or longer from initial treatment in patients who have relapsed. 
Ponovno liječenje sastoji se od dodatne intravenske infuzije 5 mg zoledronatne kiseline nakon perioda od jedne godine ili duljem od početnog liječenja bolesnika u kojih se bolest ponovno pojavila.
- Patients with hypocalcaemia (see section 4.4). 
- Bolesnici s hipokalcemijom (vidjeti dio 4.4).
The majority of the side effects, such as fever and chills, pain in the muscles or joints, and headache, occur within the first three days following the dose of Zoledronic Acid Hospira. 
Većina nuspojava, poput vrućice i zimice, bolova u mišićima ili zglobovima te glavobolje javlja se unutar prva tri dana nakon primjene doze Zoledronatne kiseline Hospira.
Zoledronic acid was not mutagenic in the mutagenicity tests performed and carcinogenicity testing did not provide any evidence of carcinogenic potential. 
Zoledronatna kiselina nije pokazala mutagenost na provedenim testovima mutagenosti, a ispitivanje kancerogenosti nije pružilo nikakav dokaz kancerogenog potencijala.
The incidence of post-dose symptoms occurring within the first three days after administration of Zoledronic Acid Hospira can be reduced with the administration of paracetamol or ibuprofen shortly following Zoledronic Acid Hospira administration. 
Incidencija simptoma koji se javljaju u prva tri dana nakon primjene doze Zoledronatne kiseline Hospira mogu se smanjiti uzimanjem paracetamola ili ibuprofena nedugo nakon uzimanja Zoledronatne kiseline Hospira.
The main molecular target of zoledronic acid in the osteoclast is the enzyme farnesyl pyrophosphate synthase. 
Glavni molekularni cilj zoledronatne kiseline u osteoklastu je enzim farnezil pirofosfat sintaza.
Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. 
Unutar svake skupine učestalosti nuspojave su prikazane prema padajućoj ozbiljnosti.
In clinical studies, zoledronic acid has been administered concomitantly with commonly used anticancer agents, diuretics, antibiotics and analgesics without clinically apparent interactions occurring. 
U kliničkim ispitivanjima zoledronatna kiselina primjenjivala se istodobno s uobičajeno primijenjenim antitumorskim lijekovima, diureticima, antibioticima i analgeticima bez klinički vidljivih interakcija.
In the clinical studies, zoledronic acid treatment was resumed only when the creatinine level returned to within 10% of the baseline value (see section 4.4). 
U kliničkim je ispitivanjima liječenje zoledronatnom kiselinom nastavljeno tek kad se razina kreatinina vratila na vrijednosti unutar 10% početne vrijednosti (vidjeti dio 4.4).
− Studies with several types of infusion lines made from polyvinylchloride, polyethylene and polypropylene showed no incompatibility with zoledronic acid. 
- Ispitivanja s nekoliko vrsta infuzijskih linija od polivinilklorida, polietilena i polipropilena nisu pokazala inkompatibilnost sa zoledronatnom kiselinom.
Due to the rapid onset of effect of zoledronic acid on bone turnover, transient hypocalcaemia, sometimes symptomatic, may develop and is usually maximal within the first 10 days after infusion of zoledronic acid (see section 
Zbog brzog nastupa učinka zoledronatne kiseline na pregradnju kostiju može se razviti prolazna hipokalcemija, ponekad simptomatska, koja se može razviti i obično je najviša unutar prvih 10 dana nakon infuzije zoledronatne kiseline (vidjeti dio 4.8).
In the clinical trials, renal deterioration was defined as follows: 
U kliničkim je ispitivanjima pogoršanje funkcije bubrega bilo definirano na sljedeći način:
Since zoledronic acid is not metabolised in humans and the substance was found to have little or no capacity as a direct-acting and/or irreversible metabolism-dependent inhibitor of P450 enzymes, zoledronic acid is unlikely to reduce the metabolic clearance of substances which are metabolised via the cytochrome P450 enzyme systems. 
Budući da se zoledronatna kiselina ne metabolizira u ljudi, a da je utvrđeno da ima malu ili nikakvu sposobnost da, djelujući direktno i/ili kao ireverzibilni inhibitor ovisan o metabolizmu, inhibira P450 enzime, nije vjerojatno da će zoledronatna kiselina smanjiti metabolički klirens tvari koje se metaboliziraju preko enzimskog sustava citokroma P450.
The majority of these reactions occur within the first three days following zoledronic acid administration. 
Većina tih nuspojava pojavila se unutar prva tri dana nakon primjene zoledronatne kiseline.
The selective action of bisphosphonates on bone is based on their high affinity for mineralised bone. 
Selektivno djelovanje bisfosfonata na kost temelji se njihovom visokom afinitetu za mineraliziranu kost.
Treatment of Paget's disease of the bone in adults. 
Liječenje Pagetove bolesti kostiju u odraslih.
The majority of the reports refer to cancer patients following tooth extractions or other dental surgeries. 
Većina prijavljenih slučajeva odnosila se na onkološke bolesnike nakon vađenja zuba ili drugih stomatoloških operacija.
Zoledronic acid 8 mg (N=90) 
zoledronatna kiselina 8 mg (n=90)
Re-treatment of Paget's disease: After initial treatment with zoledronic acid in Paget's disease, an extended remission period is observed in responding patients. 
Ponovno liječenje Pagetove bolesti: Nakon početnog liječenja Pagetove bolesti zoledronatnom kiselinom, produženi period remisije opažen je u bolesnika koji su dobro reagirali na liječenje.
• Creatinine clearance should be calculated based on actual body weight using the Cockcroft-Gault formula before each Zoledronic Acid Hospira dose. 
• potrebno je izračunati klirens kreatinina na temelju stvarne tjelesne težine pomoću CockcroftGault formule prije svake doze Zoledronatne kiseline Hospira
Increasing the infusion time from 5 to 15 minutes caused a 30% decrease in zoledronic acid concentration at the end of the infusion, but had no effect on the area under the plasma concentration versus time curve. 
Produljenje trajanja infuzije s 5 na 15 minuta prouzročilo je 30%-tno sniženje koncentracije zoledronatne kiseline na kraju infuzije, ali nije imalo nikakvog učinka na područje ispod krivulje koncentracije u plazmi naspram vremena mjerenja.
It is given as a single 15-minute intravenous infusion in a separate infusion line. 
Primjenjuje se kao jednokratna 15-minutna intravenska infuzija kroz zasebnu infuzijsku liniju.
Teratogenicity was observed in rats at doses 0.2 mg/kg and was manifested by external, visceral and skeletal malformations. 
Teratogenost je opažena u štakora pri dozama ≥ 0,2 mg/kg, a izražavala se vanjskim i visceralnim malformacijama te malformacijama skeleta.
Patients should also be administered an oral calcium supplement of 500 mg and 400 IU vitamin D daily. 
Bolesnicima također treba davati oralni nadomjestak kalcija od 500 mg i 400 IU vitamina
Six patients who achieved therapeutic response 6 months after treatment with zoledronic acid and later experienced disease relapse during the extended follow-up period were re-treated with zoledronic acid after a mean time of 6.5 years from initial treatment to re-treatment. 
Šest bolesnika koji su postigli terapijski odgovor 6 mjeseci nakon liječenja zoledronatnom kiselinom, a koji su kasnije doživjeli relaps bolesti tijekom produljenog perioda praćenja, ponovno su liječeni zoledronatnom kiselinom, a srednje vrijeme od početnog liječenja do ponovnog liječenja bilo je 6,5 godina.
From the bone tissue it is released very slowly back into the systemic circulation and eliminated via the kidney. 
Iz koštanog tkiva se otpušta vrlo sporo natrag u sistemsku cirkulaciju i eliminira putem bubrega.
The recommended dose is a single intravenous infusion of 5 mg zoledronic acid. 
Preporučena doza je jednokratna intravenska infuzija 5 mg zoledronatne kiseline.
In a large clinical trial, local reactions at the infusion site, such as redness, swelling and/or pain, were reported (0.7%) following the administration of zoledronic acid. 
U velikom kliničkom ispitivanju prijavljene su lokalne reakcije na mjestu primjene infuzije (0,7%), kao što su crvenilo, oticanje i/ili bol, nakon primjene zoledronatne kiseline.
Zoledronic Acid Hospira, further diluted in 100 ml (see section 6.6), should be given as a single intravenous infusion in no less than 15 minutes. 
Zoledronatnu kiselinu Hospira, dodatno razrijeđenu u 100 ml (vidjeti dio 6.6), treba primijeniti kao jednokratnu intravensku infuziju u trajanju od najmanje 15 minuta.
Other products containing zoledronic acid as active substance are available for oncology indications. 
Ostali lijekovi koji sadrže zoledronatnu kiselinu kao djelatnu tvar dostupni su za onkološke indikacije.
In patients with Paget's disease, symptoms due to low blood calcium, such as muscle spasms, or numbness, or a tingling sensation especially in the area around the mouth have been reported. 
U bolesnika s Pagetovom bolešću prijavljeni su simptomi uzrokovani niskom razinom kalcija u krvi, kao što su grčevi mišića ili utrnutost ili trnci, osobito u području oko usta.
Your doctor will advise you and decide how long you should be treated with Zoledronic Acid Hospira. 
Liječnik će Vam dati savjet i odlučiti koliko dugo biste se trebali liječiti Zoledronatnom kiselinom Hospira.
Healthcare professionals are advised not to dispose of unused Zoledronic Acid Hospira via the domestic sewage system. 
Zdravstvenim radnicima se savjetuje da ne bacaju neiskorištenu Zoledronatnu kiselinu Hospira u otpadne vode.
The following are the important identified risks with zoledronic acid in the approved indications: 
Utvrđeni su sljedeći važni rizici primjene zoledronatne kiseline u odobrenim indikacijama:
Very common (may affect more than 1 in 10 people):− Low level of phosphate in the blood. 
Vrlo često (može se javiti u do 1 na 10 osoba): - niska razina fosfata u krvi.
In the event of overdose leading to clinically significant hypocalcaemia, reversal may be achieved with supplemental oral calcium and/or an intravenous infusion of calcium gluconate. 
U slučaju da predoziranje dovodi do klinički značajne hipokalcemije, suprotni učinak se može postići nadomještanjem oralnog kalcija i/ili intravenskom infuzijom kalcijevog glukonata.
− Keep Zoledronic Acid Hospira out of the reach and sight of children. 
- Zoledronatnu kiselinu Hospira čuvajte izvan pogleda i dohvata djece.
Zoledronic acid was evaluated in rats for potential adverse effects on fertility of the parental and F1 generation. 
Moguće nuspojave zoledronatne kiseline na plodnost ispitane su na roditeljskoj i F1 generaciji štakora.
Arthritis and joint swelling as a symptom of acute phase reaction 
artritis i oticanje zglobova kao simptomi reakcije akutne faze
It comes in 100 ml plastic bags as a readyto-use solution for infusion. 
Isporučuje se u plastičnim vrećicama od 100 ml kao otopina za infuziju spremna za uporabu.
- Pregnancy and breast-feeding (see section 4.6). 
- Trudnoća i dojenje (vidjeti dio 4.6).
CARTON FOR 1 BAG AS UNIT PACK 
KUTIJA ZA 1 VREĆICU KAO JEDINIČNO PAKIRANJE
Zoledronic acid has been associated with renal impairment manifested as deterioration in renal function (i.e. increased serum creatinine) and in rare cases acute renal failure. 
Zoledronatna kiselina je bila povezana s oštećenjem bubrega koje se očitovalo kao slabljenje bubrežne funkcije (npr. povišeni kreatinin u serumu) i u rijetkim slučajevima kao akutno zatajenje bubrega.
Zoledronic acid should not be used during pregnancy. 
Zoledronatna kiselina ne smije se primjenjivati tijekom trudnoće.
Based on the review of both clinical trial and post-marketing cases, there is sufficient evidence to support an association between zoledronic acid therapy, the reported event of hypocalcaemia, and the secondary development of cardiac arrhythmia. 
Na temelju pregleda kliničkih i postmarketinških ispitivanja, postoji dovoljno dokaza koji podupiru povezanost liječenja zoledronatnom kiselinom i prijavljenih slučajeva hipokalcemije i posljedičnog razvoja srčane aritmije.
− The diluted Zoledronic Acid Hospira infusion solution should be used immediately in order to avoid microbial contamination. 
- Razrijeđena otopina za infuziju Zoledronatne kiseline Hospira mora se primjeniti odmah da bi se izbjeglo mikrobno zagađenje.
These fractures occur after minimal or no trauma and some patients experience thigh or groin pain, often associated with imaging features of stress fractures, weeks to months before presenting with a completed femoral fracture. 
Prijelomi nastaju nakon minimalne traume ili bez ikakve traume, pri čemu neki bolesnici osjete bol u bedru ili preponama, a na radiološkim slikama često su prisutni znakovi stresnog prijeloma tjednima ili mjesecima prije nego što nastane potpuni prijelom bedrene kosti.
In multiple myeloma patients, the risk of renal dysfunction may be increased when zoledronic acid is used in combination with thalidomide. 
U bolesnika s multiplim mijelomom, rizik od poremećaja funkcije bubrega može biti povećan kad se primjenjuje zoledronatna kiselina u kombinaciji s talidomidom.
Of the 153 zoledronic acid-treated patients and 115 risedronate-treated patients who entered an extended observation study, after a median duration of follow-up of 3.8 years from time of dosing, the proportion of patients ending the Extended Observation Period due to the need for re-treatment (clinical judgment) was higher for risedronate (48 patients, or 41.7%) compared with zoledronic acid (11 patients, or 7.2%). 
Od 153 bolesnika liječenih zoledronatnom kiselinom i 115 bolesnika liječenih risedronatom, koji su ušli u produljenu studiju praćenja, nakon medijana trajanja praćenja od 3,8 godina, računato od vremena doziranja, stopa bolesnika koji su završili produljeni period praćenja zbog potrebe za ponovnim liječenjem (klinička procjena) bila je veća za risedronat (48 bolesnika ili 41,7%) naspram zoledronatne kiseline (11 bolesnika ili 7,2%).
− For single use only. 
Samo za jednokratnu primjenu.
Patients who have received doses higher than those recommended (see section 4.2) should be carefully monitored, since renal function impairment (including renal failure) and serum electrolyte (including calcium, phosphorus and magnesium) abnormalities have been observed. 
Bolesnike koji su primili više doze od preporučenih (vidjeti dio 4.2) treba pažljivo pratiti budući da su primijećena oštećenja bubrega (uključujući zatajenje bubrega) i poremećaji serumskih elektrolita (uključujući kalcij, fosfor i magnezij).
The incidence of these reactions decreased markedly with subsequent annual doses of zoledronic acid. 
Incidencija tih nuspojava značajno se smanjila s narednim godišnjim dozama zoledronatne kiseline.
Median time to onset of the first SRE was not reached in the zoledronic acid -treated arm at the end of the study and was significantly prolonged compared to placebo (p=0.007). 
Medijan vremena do nastupa prvog koštanog događaja nije dosegnut u skupini liječenoj zoledronatnom kiselinom do kraja ispitivanja i bio je značajno dulji naspram placeba (p=0,007).
Pharmacokinetic/pharmacodynamic relationships 
Odnos farmakokinetika/farmakodinamika
Convulsions, hypoaesthesia and tetany (secondary to hypocalcaemia) 
konvulzije, hipoestezija i tetanija (zbog hipokalcemije)
- 4.4 ml for 3.5 mg dose - 4.1 ml for 3.3 mg dose - 3.8 ml for 3.0 mg dose 
- 4,4 ml za dozu od 3,5 mg - 4,1 ml za dozu od 3,3 mg - 3,8 ml za dozu od 3,0 mg
Adverse reactions, such as dizziness and somnolence, may have influence on the ability to drive or use machines, therefore caution should be exercised with the use of zoledronic acid along with driving and operating of machinery. 
Nuspojave poput omaglice i somnolencije mogu utjecati na sposobnost upravljanja vozilima i rada sa strojevima te je stoga potreban oprez kad se tijekom primjene zoledronatne kiseline upravlja vozilima i radi sa strojevima.
Elevated bone turnover is a characteristic of Paget's disease of the bone. 
Povećana pregradnja kosti je osobina Pagetove bolesti kostiju.
Other medicines and Zoledronic Acid Hospira Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines. 
Drugi lijekovi i Zoledronatna kiselina Hospira Obavijestite svog liječnika, ljekarnika ili medicinsku sestru ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.